NCT04665895View on ClinicalTrials.gov

A Clinical Trial for Examining the Therapeutic Equivalence Between Fluticasone Propionate 100 mcg/Blister Oral Inhalation Powder/Respirent Pharmaceuticals vs. FLOVENT DISKUS® 100mcg/Blister Oral Inhalation Powder/GSK in Patients With Asthma

PHASE3CompletedINTERVENTIONAL

Enrollment

451

Participants

Timeline

Start Date

December 9, 2020

Primary Completion Date

August 13, 2021

Study Completion Date

February 22, 2022

Conditions

Asthma

Interventions

DRUG

Fluticasone propionate 100 mcg/blister oral inhalation powder/Respirent Pharmaceuticals

twice daily inhalation throughout the study

DRUG

FLOVENT DISKUS® 100 mcg/blister oral inhalation powder/GSK

twice daily inhalation throughout the study

DRUG

Placebo

twice daily inhalation throughout the study

Trial Locations (1)

Unknown

BECRO Ltd., Athens

All Listed Sponsors

collaborator

Becro Ltd.

INDUSTRY

lead

Respirent Pharmaceuticals Co Ltd.

INDUSTRY

NCT04665895 - A Clinical Trial for Examining the Therapeutic Equivalence Between Fluticasone Propionate 100 mcg/Blister Oral Inhalation Powder/Respirent Pharmaceuticals vs. FLOVENT DISKUS® 100mcg/Blister Oral Inhalation Powder/GSK in Patients With Asthma | Biotech Hunter | Biotech Hunter